



OPEN ACCESS

# Preferential *MGMT* hypermethylation in SDH-deficient wild-type GIST

Olivier T Giger <sup>1</sup>, Rogier ten Hoopen, <sup>2</sup> David Shorthouse <sup>3</sup>, Shukri Abdullahi, <sup>1</sup> Venkata Ramesh Bulusu, <sup>4</sup> Saili Jadhav, <sup>2</sup> Eamonn R Maher, <sup>5</sup> Ruth T Casey <sup>5</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jcp-2022-208462>).

<sup>1</sup>Pathology, University of Cambridge, Cambridge, UK

<sup>2</sup>Oncology, University of Cambridge, Cambridge, UK

<sup>3</sup>Department of Medical Physics and Biomedical Engineering, University College London, London, UK

<sup>4</sup>Oncology, Addenbrooke's Hospital, Cambridge, UK

<sup>5</sup>Department of Medical Genetics and Cancer Research, University of Cambridge, Cambridge, UK

## Correspondence to

Dr Olivier T Giger, Pathology, University of Cambridge, Cambridge CB2 1TN, UK; [olivier.giger@nhs.net](mailto:olivier.giger@nhs.net)

Received 28 June 2022

Accepted 16 September 2022

Published Online First

5 October 2022

## ABSTRACT

**Aims** Wild-type gastrointestinal stromal tumours (wtGIST) are frequently caused by inherited pathogenic variants, or somatic alterations in the succinate dehydrogenase subunit genes (*SDHx*). Succinate dehydrogenase is a key enzyme in the citric acid cycle. SDH deficiency caused by *SDHx* inactivation leads to an accumulation of succinate, which inhibits DNA and histone demethylase enzymes, resulting in global hypermethylation. Epigenetic silencing of the DNA repair gene *MGMT* has proven utility as a positive predictor of the therapeutic efficacy of the alkylating drug temozolomide (TMZ) in tumours such as glioblastoma multiforme. The aim of this study was to examine *MGMT* promoter methylation status in a large cohort of GIST. **Methods** *MGMT* methylation analysis was performed on 65 tumour samples including 47 wtGIST (33 SDH-deficient wtGIST and 11 SDH preserved wtGIST) and 21 tyrosine kinase (TK) mutant GIST. **Results** *MGMT* promoter methylation was detected in 8 cases of SDH-deficient (dSDH) GIST but in none of the 14 SDH preserved wild-type GIST or 21 TK mutant GIST samples analysed. Mean *MGMT* methylation was significantly higher ( $p=0.0449$ ) and *MGMT* expression significantly lower ( $p<0.0001$ ) in dSDH wtGIST compared with TK mutant or SDH preserved GIST. No correlation was identified between *SDHx* subunit gene mutations or *SDHC* epimutation status and mean *MGMT* methylation levels. **Conclusion** *MGMT* promoter hypermethylation occurs exclusively in a subset of dSDH wtGIST. Data from this study support testing of tumour *MGMT* promoter methylation in patients with dSDH wtGIST to identify those patients who may benefit from most from TMZ therapy.

## BACKGROUND

Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours of the gastrointestinal tract with an incidence of 15–20 per million of the population.<sup>1,2</sup> Most GISTs occurring in adults are driven by activating somatic mutations in the receptor tyrosine kinase genes *KIT*<sup>3</sup> or *PDGFRA*<sup>4</sup> and mutations in these proto-oncogenes predict an excellent response to tyrosine kinase inhibitors.<sup>5</sup> Wild-type GIST (wtGIST) refers to those which are negative for activating mutations in *KIT* and *PDGFRA*.<sup>5</sup> These account for 15% of adult and 85% of paediatric GIST. The majority of wtGIST are caused by a loss of function in the succinate dehydrogenase (SDH) enzyme complex, most commonly caused by an inherited mutation in one of the four *SDHx*

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Gastrointestinal stromal tumours (GIST) with mutations in the succinate dehydrogenase (SDH) protein complex are resistant to current treatment regimes in other GIST. Alkylating agents may be used for treatment of tumours which show loss of *MGMT* function due to DNA methylation of its promoter. The aim of this study was to assess whether *MGMT* promoter methylation was a common finding in SDH-deficient GIST.

## WHAT THIS STUDY ADDS

⇒ Our data shows that *MGMT* promoter methylation is frequent if not exclusive to SDH-deficient GIST. The tumour *MGMT* methylation status may also have a role as a prognostic biomarker and could inform on potential therapeutic options for SDH-deficient GIST.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Data from this study suggest that diagnostic testing for *MGMT* promoter methylation should be considered as part of diagnostic clinical testing for SDH-deficient GIST.

genes (*SDHA*, *SDHB*, *SDHC* and *SDHD*)<sup>5</sup> or by tumour-specific *SDHC* silencing by promoter methylation.<sup>6</sup> *SDHx* mutations impair SDH enzyme complex assembly at the inner mitochondrial membrane or cause a loss of the enzyme complex function. These tumours are therefore referred to as SDH deficient (dSDH). The association of *SDHx* mutations with a hereditary tumour syndrome was first described in familial pheochromocytoma and paraganglioma (PPGL).<sup>7</sup> Over the past two decades, the spectrum of tumours associated with SDH deficiency has been extended to include GIST, renal cell carcinomas (RCC) and pituitary adenomas.<sup>8</sup> The SDH enzyme couples the oxidation of succinate to fumarate in the citric acid cycle and a loss of function in tumour cells leads to accumulation of succinate. Excess levels of succinate inhibit the 2-oxyglutarate dependent dioxygenase enzymes including the Jumonji C (JmjC) histone demethylase class of enzymes and the ten eleven translocase DNA demethylase enzymes.<sup>9</sup> Genome-wide methylation profiling of *SDHx* mutated tumours has demonstrated DNA hypermethylation in PPGL<sup>9</sup> and wtGIST.<sup>10</sup> This has prompted interest in the potential therapeutic utility of precision medicine



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

**To cite:** Giger OT, ten Hoopen R, Shorthouse D, et al. *J Clin Pathol* 2024;**77**:34–39.

approaches targeting hypermethylated tumour suppressor genes in these tumours.

6-methylguanine-DNA methyltransferase (*MGMT*) encodes a DNA repair protein that removes alkyl groups from the guanine residue within DNA. DNA alkylation most commonly occurs at guanine residues (O6-guanine, N7-guanine) and leads to single and double-strand DNA breaks and therefore, if not repaired, to subsequent apoptotic cell death. *MGMT* expression within cancer cells allows the cell to recover from the DNA damaging effects of alkylating agents enabling the tumour to become resistant to therapeutic use of such agents. Epigenetic silencing of *MGMT* by promoter hypermethylation has been described in malignancies of the colon and rectum (39%), central nervous system (34%), head and neck (32%), lung (21%), lymphoma (25%), oesophagus (20%) and pancreas (11%).<sup>11</sup> The status of *MGMT* expression has been proven to be of significant clinical benefit in the management of glioblastoma multiforme, where epigenetic silencing of *MGMT* by promoter hypermethylation informs therapeutic response to temozolomide.<sup>12</sup> A correlation between germline *SDHB* status and *MGMT* promoter methylation has been demonstrated in PPGL<sup>13</sup> and the authors of this study postulated that the reduced *MGMT* expression due to promoter hypermethylation was responsible for the favourable response to temozolomide (TMZ) in the cohort of patients with *SDHB* mutations. More recently, *MGMT* was found to be preferentially methylated in a small subset of SDH-deficient (dSDH) wild-type GIST compared with a larger subset of SDH preserved (pSDH) wild type GIST (6/9 (67%) dSDH GIST, vs 6/39 (15%) pSDH-preserved GISTs.<sup>14</sup> Lou *et al* observed a significantly higher percentage of *MGMT* promoter hypermethylation in SDH deficient and epithelioid/mixed non-TK mutant GIST (4/7 and 8/44, respectively).<sup>15</sup>

At present, there are few effective oncological therapies to treat patients with inoperable metastatic dSDH wtGIST. The outcome of an open-label, phase 2 efficacy study of TMZ in advanced SDH-mutant/deficient wtGIST (ClinicalTrials.gov Identifier: NCT03556384) is awaited but earlier studies have suggested that *MGMT* methylation status could be used as a biomarker to identify individuals with metastatic wtGIST, who might have a favourable response to TMZ therapy.

### Study aims

The aims of this study were (1) to profile *MGMT* promoter methylation status and *MGMT* expression in a large UK cohort of wtGIST and (2) to inform the utility of *MGMT* methylation analysis as a routine clinical diagnostic test for patients with metastatic wtGIST for whom systemic therapy is being considered.

## METHODS

### Clinical sample collection

Cases were ascertained from the National Paediatric and Adult wild type GIST (PAWS GIST UK) and GIST clinic at Cambridge University Hospital NHS Foundation Trust. Details of clinical phenotype, family history, histopathology and germline molecular testing results were collated from patient records.

### Study design

This was a retrospective study. wtGIST patients, for whom formalin-fixed paraffin embedded (FFPE) tumour blocks or fresh frozen (FF) tumour tissue were available, were eligible for inclusion. The SDH status for all tumours had been assessed by SDHB immunohistochemistry. A control set of *KIT*, *PDGFRA*, *NF1* and quadruple-wt GISTs (n=32) was included. The FFPE

tumour blocks from the primary tumour were available for all cases and FF tissue from the primary tumour was available for four cases. Analysis was also performed for a subset of patients (n=2) for whom FFPE tumour blocks from the primary and metastatic tumour were available.

### Tissue dissection for DNA and RNA isolation

Preselected paraffin blocks containing tumour were used for molecular analysis. Histologically confirmed tumour and tumour-free tissue suitable for DNA isolation was identified by an experienced molecular histopathologist (OG). The tumour cell content in the selected areas ranged between 50% and 80%. The 6–10 µm thick FFPE sections were mounted on glass slides. Tumour and normal tissue were scraped of the slides barring a security margin between tumour and normal of 2 mm.

### Clinical germline DNA sequencing

DNA was extracted from peripheral blood samples according to standard protocols. Next-generation sequencing of a clinical gene panel including; *SDHA*, *SDHB*, *SDHC*, *SDHD*, *KIT*, *PDGFRA* and *NF1* was performed by the laboratory staff at Cambridge University Hospital NHS Foundation Trust or Birmingham Women's and Children's Hospital NHS Trust using the TruSightOne or TruSight Cancer sequencing panels (Illumina, UK). An average coverage depth of >20 fold was achieved for 98% of the regions sequenced. All detected variants were confirmed by Sanger sequencing. Whole exon deletions and duplications and large rearrangements are not detected using this method and multiple ligation probe analysis was performed for *SDHB*, *SDHC* and *SDHD*.

### DNA extraction

DNA was extracted from FFPE tissue according to standard protocols. For details, please see online supplemental data.

### RNA extraction from FF tissue

RNA from FF and FFPE tissue was isolated according to standard protocols. For details, please refer to online supplemental data.


### Bisulfite conversion

Bisulfite conversion was performed using the Qiagen Epitect Bisulfite kit (Cat 59104) or the Zymo Research EZ DNA Methylation kit (D5001) according to the manufacturers' instructions. viii) Analysis of *MGMT* and *SDHC* promoter methylation.

1–25 ng bisulfite converted DNA was used for *MGMT* and *SDHC* promoter methylation analysis.

For *MGMT* 375 nM forward primer, with a 20-mer 5' M13 overhang (TGTAACGACG-GCCAGTTTATAGTTTTYGGAT ATGTTGGGATAG) and 187.5 nM of biotinylated reverse primer ((btn)-TCCCAAACACTCACCAAATC) were used. For sequencing a nested sequencing primer (GTTTTTGAACG TTTTGYGTTT) was used.

For *SDHC* 375 nM forward primer a 20-mer 5' M13 overhang, (TGTAACGACG-GCCAGTTTATAGGAGAAGTT TTAGAGTTTTTTAAAGAG) and 250 nM of biotinylated reverse primer ((btn)-AAAATAACRCCAAACRACCCC) were used. For *SDHC* a nested sequencing primer (GTTATATGATAT TTTTAAATTT) was used. *MGMT* promoter hypermethylation was defined as a mean *MGMT* methylation and *SDHC* across CpG islands 1–8 of >10% for this study. For details, please refer to online supplemental data.



**Figure 1** Assessment of *MGMT* promoter status in previously published GIST data. (A) *MGMT* probe methylation status for GIST patients dSDH (N=68) and pSDH (N=92) from Killian *et al.*<sup>10</sup> P value represents Student's t-test. (B) RNA normalised expression for *MGMT* in GIST patients with different mutations in *SDH* genes from Killian *et al.*<sup>18</sup> P value represents one-way analysis of variance (ANOVA). GIST, gastrointestinal stromal tumour.

### MGMT expression analysis with quantitative RT-PCR

RNA (125–250 ng) was transcribed into cDNA with random hexamers. Relative *MGMT* expression was analysed according to<sup>16,17</sup> with SYBR Green using the PowerUp SYBR Green Master Mix (Applied Biosystems, ref 01061935), with *MGMT* oligo's; forward 5'-GCTGAATGCCTATTTCCACCA-3'/reverse 5'-CACAACTTCAGCAGCTTCCA-3'; normalised to the average Ct value of three internal reference genes: *HPRT1*, *GUSB*, *TBP*. The delta Ct was calculated by subtracting the mean of triplicate Ct values for *MGMT* with the mean of the triplicate Ct values of all three reference genes.

### Statistical analysis

Statistical analyses were performed using GraphPath Prism V.6. Groups were compared by ANOVA (Kruskal-Wallis), assuming non-Gaussian distribution. Comparisons between *MGMT* methylation and *MGMT* expression between groups was performed using unpaired Mann-Whitney t-test assuming a non-Gaussian distribution. Analysis of *MGMT* methylation in tumours vs adjacent normal tissue was performed using a paired t-test and correlations between mean *MGMT* methylation and clinical and pathological features was performed using an unpaired t-test.

### Analysis of public data

Methylation and affymetrix expression data for GISTs was downloaded from the repositories for Killian *et al.*<sup>10</sup> and Killian *et al.*<sup>18</sup> (GEO ids 34387 and 56670, respectively) (15)(10). PPGL data were downloaded from online supplemental table S2 of Hadoux *et al.*<sup>16</sup> TCGA data were downloaded using Xenabrowse<sup>19</sup> the 'Pan-cancer atlas'.<sup>20</sup> *MGMT* methylation for figure 1A was calculated using the average (mean) of both available probes (*MGMT\_P272\_R*, *MGMT\_P281\_F*). For PPGL data, *MGMT* promoter methylation was calculated as the average (mean) of probes found to be differently methylated and that correlate with *MGMT* expression in Hadoux *et al.* (cg25946389, cg12434587, cg12981137, cg02941816).<sup>16</sup> Analysis was performed using Python. P values represent Student's t-tests, one-way ANOVA or Tukey post hoc tests performed using the SciPy<sup>21</sup> (Student's t-tests, ANOVA) or statsmodels (Tukey) libraries.

**Table 1** Clinicopathological features of study cohort

Clinicopathological features	N=(%)
Age	Mean age 46.7 years (range 13–79 years)
Gender	32 female (49.3%), 24 male (36.9%), 9 unknown (13.8%)
Primary site of GIST	Gastric 45 (69.2%), small bowel 12 (18.5%), unknown 8 (12.3%)
Metastatic	Yes 19 (29.2%), no 38 (58.5%), unknown 8 (12.3%)
Synchronous tumour	Yes 8 (12.3%) (6 PPGL, 2 pulmonary chondroma) No 49 (75.4%), unknown 8 (12.3%)
Histological subtype of GIST	Epithelioid 7 (10.8%), mixed 23 (35.4%), spindle 14 (21.5%) unknown 21 (32.3%)
Proliferation index	Mean 5% range (1%–80%)
GIST, gastrointestinal stromal tumour.	

### RESULTS

*MGMT* methylation analysis was performed on 68 tumour samples from 65 individual patients including 47 wtGIST (67.7%) and 21 (32.3%) TK mutant (17 *KIT* and 4 *PDGFRA*) GIST (30.9%). Complete clinical and pathological data was available for 54 patients (79.4%). The mean age in the study cohort was 46.7 years (range 13–79 years). The cohort included 32 female (49.3%) and 24 male (36.9%) patients (information on gender was not available for 9 patients (13.8%)).

Nineteen (29.2%) patients had metastatic disease and eight patients had synchronous tumours (six PPGL and two pulmonary chondromas; see table 1); (see online supplemental table S1). A germline *SDHx* mutation was identified in 17 cases of dSDH wtGIST. Tumour *SDHC* promoter methylation was identified in 12 cases of dSDH wtGIST of which nine had no identifiable germline *SDHx* mutation. The germline genetic test results were unavailable for four cases.

### MGMT methylation and correlation with molecular status

Mean *MGMT* promoter methylation level for the 65 GIST studied varied by GIST subgroup: mean *MGMT* methylation was 2.905% (SEM=1.758) for TK mutant GIST (N=21), 3.143% (SEM=0.4041) for NF1 (N=7) vs 2.25% (SEM=0.75 SEM) for quadruple negative GIST (N=4) and 8.091% (SEM=1.786) for SDH-deficient GIST (N=33) (p=0.0449)(table 2). Overall *MGMT* promoter methylation (defined as mean methylation >10%) was identified in 8 of 65 cases (12.3%). All 8 cases were dSDH wtGIST (8/33, 24.2%). *MGMT* promoter hypermethylation was not identified in any of the 11 SDH preserved wtGIST or the 21 TK mutant GIST samples analysed. There was no difference in mean methylation comparing SDH tumours caused by *SDHC* epimutation (mean methylation 7.5566.583% (SEM=2.897207) to those with germline mutations in *SDHA* (mean methylation 4.556% (SEM=1.192) or other *SDHx* subunit gene mutations (*SDHB/C/D*) (mean methylation 8.5% (SEM 5.099), Kruskal-Wallis ANOVA p=0.9167.

### MGMT expression

*MGMT* expression by qRT-PCR was performed on tumours from 25 patients from whom FF tissue was available. Relative mean *MGMT* expression expressed as -dCT was assessed by RT-Q-PCR using FF tissue available for 25 samples. Relative mean *MGMT* expression was significantly different for dSDH wtGIST (N=16) vs TK mutant GIST (N=9) (-2.194; SD 1.353 vs 0.33; SD 0.495, Mann-Whitney t-test (p<0.0001)). The relative mean *MGMT* expression for dSDH

**Table 2** Molecular features of the SDH-deficient GIST cohort

Tumour ID	KIT/PDGFR $\alpha$ mutation status	SDH status	Germline gene mutation	SDHC epimutation	Tumour SDHC methylation	Mean MGMT methylation
G0001	WT	dSDH	No	Y	76%	2%
G0002	WT	dSDH	<i>SDHC c.380A&gt;G (p. His127Arg)</i>	Y	46%	2%
G0003	WT	dSDH	No	N	1%	23%
G0006	WT	dSDH	<i>SDHA c.1765C&gt;T (p. Arg589Trp)</i>	N	5%	5%
G0010	WT	dSDH	<i>SDHD c.296delT (p. Leu99fs)</i>	N	2%	44%
G0011	WT	dSDH	<i>SDHA c.91C&gt;T (p. Arg31Ter)</i>	N	2%	3%
G0012	WT	dSDH	<i>SDHD c.34G&gt;A (p. Gly12Ser*)</i>	Y	46%	4%
G0013	WT	dSDH	No germline pathogenic variant detected	Y	54%	5%
G0017	WT	dSDH	No germline pathogenic variant detected	Y	79%	3%
G0018	WT	dSDH	<i>SDHB c.137G&gt;A (p. Arg46Gln)</i>	N	2%	2%
G0019	WT	dSDH	<i>SDHC c.148C&gt;T (p. Arg50Cys)</i>	Y	32%	5%
G0020	WT	dSDH	<i>SDHC c.43C&gt;T (p. Arg15X)</i>	N	2%	3%
G0021	WT	dSDH	<i>SDHA c.91C&gt;T (p. Arg31Ter)</i>	Y	5%	8%
G0024	WT	dSDH	No germline pathogenic variant detected	N	4%	7%
G0025	WT	dSDH	<i>SDHA c1A&gt;C, (p.MET1?)</i>	N	7%	3%
G0026	WT	dSDH	<i>SDHB c.72+1G&gt;T</i>	N	4%	6%
G0027	WT	dSDH	<i>SDHA c.150+1G&gt;A</i>	N	2%	5%
G0029	WT	dSDH	<i>SDHA c.91C&gt;T (p. Arg31Ter)</i>	N	6%	2%
G0030	WT	dSDH	<i>SDHA c.91C&gt;T (p. Arg31Ter)</i>	N	4%	3%
G0053	WT	dSDH	No germline pathogenic variant detected	Y	47%	4%
G0057	WT	dSDH	No germline pathogenic variant detected	N	4%	15%
G0081	WT	dSDH	<i>SDHB c.72+1G&gt;T</i>	N	1%	2%
G0082	WT	dSDH	No germline pathogenic variant detected	Y	80%	19%
G0085	WT	dSDH	No germline pathogenic variant detected	Y	31%	3%
G0086	WT	dSDH	No germline pathogenic variant detected	N	3%	3%
G0140	WT	dSDH	NA	N	2%	23%
G0141	WT	dSDH	NA	N	2%	33%
G0142	WT	dSDH	NA	Y	77%	3%
G0143	WT	dSDH	NA	N	2%	2%
G0144	WT	dSDH	<i>SDHA c.1909-2A&gt;G</i>	N	2%	12%
G0150	WT	dSDH	No germline pathogenic variant detected	Y	68%	3%
G0151	WT	dSDH	No germline pathogenic variant detected	Y	69%	26%
G0177	WT	dSDH	<i>SDHA c.91C&gt;T (p. Arg31Ter)</i>	N	2%	0%

GIST, gastrointestinal stromal tumour; SDH, succinate dehydrogenase.

wtGIST caused by an *SDHC* epimutation (N=4) was  $-2.563$ ; SD  $2.063$ ; vs  $-2.018$ ; SD  $1.119$  for dSDH wtGIST caused by germline *SDHx* mutations (N=12) vs  $0.330$ ; SD  $0.495$  for TK mutant GIST (N=9). Analysis of variance (ANOVA;Kruskal-Wallis)  $p=0.0004$ . For samples where paired MGMT promoter methylation and MGMT Q-RT-PCR was available, no significant correlation was found on Pearson's correlation.

### Correlation between MGMT methylation and clinicopathological parameters

Mean MGMT methylation levels were not significantly different in patients with metastatic disease ( $p=0.19$ ) vs those with single vs multiple tumours ( $p=0.31$ ), or those with a second synchronous primary tumour ( $p=0.32$ ). No correlation was identified between mean methylation levels and the tumour proliferation index ( $p=0.48$ , R-score  $-0.105$ ) or the tumour morphology ( $p=0.09$ ).

### Correlation between MGMT methylation and SDHx subunit gene mutations in GIST and other SDHx-related tumours from the literature

To validate our findings, we assessed MGMT methylation status in previously published GIST datasets. Comparing dSDH

(N=68) to pSDH (N=92) GIST samples from Killian *et al*<sup>10</sup>, we identified a significantly ( $p=0.00057$ ) higher mean MGMT methylation in dSDH GIST (figure 1A) (mean methylation in dSDH GIST  $8.1\%$ ; STD  $8.0\%$  vs pSDH GIST  $5.1\%$ ; STD  $1.4\%$ ). To assess whether a mutation in a specific *SDHx* gene is a positive predictor of MGMT methylation, we analysed the expression of MGMT in a separate cohort of GISTs for which *SDHx* subunit mutational status is known (N=20)<sup>18</sup> (figure 1B). We did not find significant differences in MGMT expression across tumours with different *SDHx* subunit gene mutations including cases with a confirmed *SDHC* epimutation (ANOVA  $p=0.43$ ).

Finally, we assessed the impact of *SDHx* mutations on MGMT methylation in a tumour dataset of PPGL (online supplemental figure S2) (N=190).<sup>16</sup> SDH-deficient PPGL demonstrated a significant ( $p<0.00001$ ) increase in MGMT promoter methylation compared with pSDH PPGL (mean methylation in dSDH PPGL  $15.5\%$ ; STD  $11.3\%$  vs pSDH PPGL  $6.6\%$ ; STD  $4.9\%$ ). We observed the previously reported significant increase in MGMT methylation for *SDHB* mutant PPGL compared with SDH preserved samples (ANOVA  $p<0.001$ , Tukey post hoc *SDHB* mut vs SDH WT  $q=0.001$ ) (online supplemental figure S2).


## DISCUSSION

The antitumour activity of TMZ has been demonstrated in a variety of MGMT-deficient tumours; including glioblastomas, gastroenteropancreatic neuroendocrine tumours and pheochromocytomas/paragangliomas.<sup>12 16 22</sup> The aim of the current study was to determine if MGMT methylation status could identify a subgroup of patients with GIST that may benefit most from TMZ therapy and to analyse potential correlations between molecular drivers of GIST, clinical and pathological parameters and MGMT methylation status.

We identified MGMT promoter hypermethylation in 8 patients and uniquely in SDH-deficient GIST (12.3% of study cohort and 22.4% of SDH-deficient GIST samples). dSDH wtGIST are a heterogeneous tumour subtype, typically presenting at a younger age and more frequently metastatic at presentation than TK-mutant GIST or SDH preserved wild-type GIST.<sup>17</sup> In contrast to TK mutant GIST, dSDH wtGIST can be indolent for long periods and median overall survival is often measured in many years,<sup>5</sup> highlighting the need for well-tolerated therapies that are most likely to yield benefit for the individual patient. SDH deficiency detected by SDHB IHC, was the only predictor of MGMT hypermethylation in this large series of wild-type and TK mutant GIST.

Specific genotype–phenotype correlations have emerged for patients with germline *SDHx* mutations; *SDHB* variants are most commonly associated with RCC *SDHD* with head and neck paragangliomas and *SDHA* with GIST.<sup>8 23 24</sup> The underlying shared mechanism of tumourigenesis for *SDHx* mutated tumours includes a complex interplay between succinate metabolism, metabolic reprogramming, redox imbalance and epigenetic regulation. The emerging genotype–phenotype correlations suggest that there may be tissue specific thresholds for altered succinate metabolism. It is assumed that the latter is further influenced by the specific *SDHx* subunit mutation and type of mutation, for example, missense versus truncating mutations.<sup>25 24–26</sup> Combining the results from our cohort with the data analysis of published datasets, no significant difference in mean MGMT methylation levels in SDH-deficient GIST with different underlying *SDHx* subunit gene mutations or *SDHC* epimutations, was identified. This is relevant as it suggests that MGMT promoter methylation analysis should be considered in all patients with wild-type GIST and in particular those with evidence of SDH deficiency on SDHB IHC, regardless of the underlying molecular driver.

In this study, we employed a pyrosequencing-based analysis of CpG's 1–8 in the promoter region of the *MGMT* gene using bisulfite converted DNA from FFPE tumour samples, adopting a protocol commonly used in routine clinical practice for glioma samples. MGMT promoter hypermethylation correlated with reduced MGMT expression levels in dSDH GIST compared with pSDH wtGIST or TK mutant GIST (figure 2D). Pyrosequencing was favoured over methylation arrays for this study because of the wider availability of FFPE embedded tumour samples and for cost effectiveness. In the UK, the national genomic test directory, recommends methylation analysis using methylation arrays and targeted testing for example, *MGMT* or *MLH1* for a number of cancers including CNS tumours and other solid organ tumours (<https://www.england.nhs.uk/publication/national-genomic-test-directories>). At present, MGMT methylation analysis is not recommended for wtGIST as part of the national test directory but data from this study and others suggests that MGMT methylation analysis should be considered for patients with wild-type GIST and in particular those with evidence of SDH deficiency on



**Figure 2** (A) Comparison of MGMT promoter methylation between dSDH and pSDH GIST; \*\*p=0.0063 (Mann-Whitney t-test). (B) Comparison of MGMT promoter methylation between dSDH, KIT/PDGFRα mutated, NF1 associated and Q-WT GIST p=0.0449 one-way ANOVA (Kruskal-Wallis); \*p=0.0134 (Mann-Whitney-test). (C) MGMT methylation in dSDH GIST groups. (D) MGMT-dCT values for expression in SDHx, SDHCepi and KIT/PDGFRα mutated GIST p=0.0004. One-way ANOVA (Kruskal-Wallis); \*\*p=0.004, \*\*\*<0.0001 (Mann-Whitney-test). GIST, gastrointestinal stromal tumour.

SDHB IHC in order to identify patients who may benefit from TMZ therapy.

MGMT methylation status has been demonstrated to be an independent predictor of overall survival for patients with high-grade gliomas, irrespective of the treatment assignment.<sup>12</sup> Interestingly, Lou *et al*'s data suggest MGMT promoter hypermethylation to be an independent favourable prognostic factor for overall and disease-free survival.<sup>15</sup> The upcoming data from the clinical trial (NCT03556384) should inform the therapeutic benefit of TMZ for patients with inoperable dSDH GIST. However, independent of its predictive significance from a therapeutic standpoint, assessing MGMT methylation status may also provide prognostic information for patients with wtGIST, analogous to in high-grade gliomas.<sup>12</sup>

In summary, our study of GIST found that MGMT promoter methylation is a recurrent epimutation exclusive to dSDH wtGIST (8 out of 33 dSDH GIST showed MGMT promoter hypermethylation, 22.4%). We found that there was no correlation between the underlying *SDHx* mutation or *SDHC* epimutation and the level of MGMT methylation, neither in our cohort of patients nor on secondary analysis of publicised datasets of GIST and PPGL. We did not identify additional clinical or pathological predictors for MGMT promoter methylation. MGMT promoter methylation analysis may be an important predictor of response to TMZ for patients with wtGIST and data from this study supports the routine utility of MGMT methylation analysis for patients with dSDH wtGIST in clinical practice.

**Handling editor** Runjan Chetty.

**Twitter** Olivier T Giger @oligig

**Contributors** OG and RTC: Project design, execution and write up of paper. RTH: write up and analyses. SA: analyses. VRB: clinical data generation. SJ: data analysis. ERM: clinic data generation. OG is responsible for the overall content as guarantor.

**Competing interests** None declared.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** This study involves human participants and was approved by Cambridge South Ethics Committee REC reference number CA/5175). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as online supplemental information. Not applicable.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Olivier T Giger <http://orcid.org/0000-0003-3390-6397>

David Shorthouse <http://orcid.org/0000-0002-3207-3584>

#### REFERENCES

- 1 Nilsson B, Bümming P, Meis-Kindblom JM, *et al.* Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. *Cancer* 2005;103:821–9.
- 2 Tryggvason G, Gíslason HG, Magnússon MK, *et al.* Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. *Int J Cancer* 2005;117:289–93.
- 3 Hirota S, Isozaki K, Moriyama Y, *et al.* Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;279:577–80. doi:10.1126/science.279.5350.577
- 4 Heinrich MC, Corless CL, Duensing A, *et al.* PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708–10. doi:10.1126/science.1079666
- 5 Boikos SA, Pappo AS, Killian JK, *et al.* Molecular subtypes of KIT/PDGFR $\alpha$  wild-type gastrointestinal stromal tumors: a report from the National Institutes of health gastrointestinal stromal tumor clinic. *JAMA Oncol* 2016;2:922–8.
- 6 Casey RT, Ten Hoopen R, Ochoa E, *et al.* SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice. *Sci Rep* 2019;9:10244.
- 7 Astuti D, Latif F, Dallol A, *et al.* Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* 2001;69:49–54.
- 8 MacFarlane J, Seong KC, Bisambar C, *et al.* A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: beyond pheochromocytoma and paraganglioma. *Clin Endocrinol* 2020;93:528–38.
- 9 Letouzé E, Martinelli C, Lorient C, *et al.* SDH mutations establish a hypermethylator phenotype in paraganglioma. *Cancer Cell* 2013;23:739–52.
- 10 Killian JK, Kim SY, Miettinen M, *et al.* Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. *Cancer Discov* 2013;3:648–57.
- 11 Esteller M, Fraga MF, Guo M, *et al.* DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. *Hum Mol Genet* 2001;10:3001–7.
- 12 Hegi ME, Diserens A-C, Gorlia T, *et al.* MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997–1003.
- 13 Hadoux J, Favier J, Scoazec J-Y, *et al.* SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. *Int J Cancer* 2014;135:2711–20 <http://www.ncbi.nlm.nih.gov/pubmed/24752622>
- 14 Ricci R, Martini M, Ravegnini G, *et al.* Preferential MGMT methylation could predispose a subset of KIT/PDGFR $\alpha$ -WT GISTs, including SDH-deficient ones, to respond to alkylating agents. *Clin Epigenetics* 2019;11:2.
- 15 Lou L, Zhang W, Li J, *et al.* Abnormal MGMT promoter methylation in gastrointestinal stromal tumors: genetic susceptibility and association with clinical outcome. *Cancer Manag Res* 2020;12:9941–52.
- 16 Hadoux J, Favier J, Scoazec J-Y, *et al.* SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. *Int J Cancer* 2014;135:2711–20.
- 17 Miettinen M, Wang Z-F, Sarlomo-Rikala M, *et al.* Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. *Am J Surg Pathol* 2011;35:1712–21.
- 18 Killian JK, Miettinen M, Walker RL, *et al.* Recurrent epimutation of SDHC in gastrointestinal stromal tumors. *Sci Transl Med* 2014;;6:268ra177–268 <http://stm.sciencemag.org/cgi/doi/>
- 19 Goldman MJ, Craft B, Hastie M, *et al.* Visualizing and interpreting cancer genomics data via the Xena platform. *Nat Biotechnol* 2020;38:675–8.
- 20 Hoadley KA, Yau C, Hinoue T, *et al.* Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. *Cell* 2018;173:291–304.
- 21 Virtanen P, Gommers R, Oliphant TE, *et al.* SciPy 1.0: fundamental algorithms for scientific computing in python. *Nat Methods* 2020;17:261–72.
- 22 Kulke MH, Hornick JL, Fraumeni JF, *et al.* O6-Methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. *Clin Cancer Res* 2009;15:338–45.
- 23 Tufton N, Sahdev A, Drake WM, *et al.* Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers? *Clin Endocrinol* 2019;90:31–46.
- 24 Evenepoel L, Papatthomas TG, Krol N, *et al.* Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. *Genet Med* 2015;17:610–20 <http://www.nature.com/articles/gim2014162>
- 25 Bayley JP, Bausch B, Jansen JC, *et al.* SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma. *J Med Genet* 2021. doi:10.1136/jmedgenet-2020-107656. [Epub ahead of print: 08 Nov 2021].
- 26 Kim E, Wright MJ, Sioson L, *et al.* Utility of the succinate: fumarate ratio for assessing SDH dysfunction in different tumor types. *Mol Genet Metab Rep* 2017;10:45–9.